MedTech & Diagnostics
Edwards Lifesciences Executive Compensation (FY25)
EW · Irvine, CA · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 8, 2026
319 figures on this page: 311 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
Bernard Zovighian was paid $17,454,255 in total compensation as Chief Executive Officer and Director for fiscal 2025, and Zovighian's total moved 19.7% higher from the $14,579,474 reported for fiscal 2024. The say-on-pay proposal drew 89.3% support at the meeting held May 7, 2026 for fiscal 2025. The disclosed peer group includes Abbott Laboratories, Agilent Technologies, Inc., Align Technology, Inc., Baxter International Inc. and Becton, Dickinson and Company, among others. The company reported 6 named executive officers for fiscal 2025.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Bernard Zovighian: $14,579,474 → $17,454,255 (19.7% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Edwards Lifesciences' chief executive and what were they paid?
Bernard Zovighian was paid $17,454,255 in total compensation as Chief Executive Officer and Director for fiscal 2025. Zovighian's total moved 19.7% higher from the $14,579,474 reported for fiscal 2024.
What was Edwards Lifesciences' say-on-pay result?
The say-on-pay proposal drew 89.3% support at the meeting held May 7, 2026 for fiscal 2025.
Which companies are in Edwards Lifesciences' peer group?
The disclosed peer group includes Abbott Laboratories, Agilent Technologies, Inc., Align Technology, Inc., Baxter International Inc. and Becton, Dickinson and Company, among others.
What is Edwards Lifesciences' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 194:1, against median employee compensation of $89,827.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Scott Ullem Corporate Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Larry Wood Corporate Vice President, Transcatheter Heart Valves | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Bernard Zovighian Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Scott Ullem Corporate Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Larry Wood Corporate Vice President, Transcatheter Heart Valves | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Bernard Zovighian Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Scott Ullem Corporate Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Larry Wood Corporate Vice President, Transcatheter Heart Valves | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Daveen Chopra Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Bernard Zovighian Chief Executive Officer and Director | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Scott Ullem Corporate Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Larry Wood Former Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Daveen Chopra Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Donald Bobo Corporate Vice President, Strategy & Corporate Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Annette Brüls Corporate Vice President, EMEACLA | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Bernard Zovighian | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Bernard Zovighian | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Bernard Zovighian | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Daveen Chopra | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Daveen Chopra | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Larry Wood | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Larry Wood | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Larry Wood | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Scott B. Ullem | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Scott B. Ullem | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Scott B. Ullem | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Bernard Zovighian | Option | ◇ | — | ◇ | 05/10/2030 |
| Option | ◇ | — | ◇ | 05/07/2032 | |
| Option | ◇ | — | ◇ | 05/06/2031 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 05/02/2029 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Scott Ullem | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 05/10/2030 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 05/07/2032 | |
| Option | ◇ | — | ◇ | 05/02/2029 | |
| Option | ◇ | — | ◇ | 05/06/2031 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Daveen Chopra | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 05/06/2031 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 05/07/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 05/10/2030 | |
| Option | ◇ | — | ◇ | 05/02/2029 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Annette Brüls | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 05/07/2032 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 07/10/2031 | |
| Donald Bobo | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 05/07/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 05/10/2030 | |
| Option | ◇ | — | ◇ | 05/06/2031 | |
| Larry Wood | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Nicholas J. Valeriani Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Leslie S. Heisz | ◇ | ◇ | — | — | — | — | ◇ |
Paul A. LaViolette | ◇ | ◇ | — | — | — | — | ◇ |
Kieran T. Gallahue | ◇ | ◇ | — | — | — | — | ◇ |
David T. Feinberg | ◇ | ◇ | — | — | — | — | ◇ |
Ramona Sequeira | ◇ | ◇ | — | — | — | — | ◇ |
Steven R. Loranger | ◇ | ◇ | — | — | — | — | ◇ |
Leslie C. Davis | ◇ | ◇ | — | — | — | — | ◇ |
Bernard Zovighian served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
| Board meeting fee | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Abbott Laboratories ABT
- Agilent Technologies, Inc. A
- Align Technology, Inc. ALGN
- Baxter International Inc. BAX
- Becton, Dickinson and Company BDX
- Boston Scientific Corporation BSX
- DexCom, Inc. DXCM
- GE Healthcare Technologies Inc. GEHC
- Hologic, Inc. HOLX
- IDEXX Laboratories, Inc. IDXX
- Illumina, Inc. ILMN
- Intuitive Surgical, Inc. ISRG
- Medtronic plc MDT
- ResMed Inc. RMD
- Stryker Corporation SYK
- The Cooper Companies, Inc. COO
- Zimmer Biomet Holdings, Inc. ZBH
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 7, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 8, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 7, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 11, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 3, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 4, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 7, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | May 8, 2019 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Edwards Lifesciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Edwards Lifesciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
319 figures on this page: 311 cited to the filing that reported them, 8 calculated from figures it prints.
311 cited to the filing
8 calculated from the filing
Documents cited
- 0001099800-26-000028Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001099800-26-000015CEO Pay Ratio · Director Compensation · Director Compensation Table – 2025 · Grants of Plan-Based Awards in Fiscal Year 2025 · and 2 more sections
- 0001099800-25-000026Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001099800-25-000013Summary Compensation Table
- 0001099800-24-000045
- 0001099800-24-000032Summary Compensation Table
- 0001193125-23-144564Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001099800-23-000013Summary Compensation Table
- 0001193125-22-140622
- 0001193125-21-151848
- 0001193125-20-137597
- 0001193125-19-141632
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Edwards Lifesciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/EW (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Edwards Lifesciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Peers Edwards Lifesciences discloses
The companies named in EW's own disclosed peer group.
Abbott LaboratoriesAgilent Technologies, Inc.Align Technology, Inc.Baxter International Inc.Becton, Dickinson and CompanyBoston Scientific CorporationDexCom, Inc.GE Healthcare Technologies Inc.Hologic, Inc.Illumina, Inc.Intuitive Surgical, Inc.Medtronic plcResMed Inc.Stryker CorporationThe Cooper Companies, Inc.Zimmer Biomet Holdings, Inc.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}